Progressive supranuclear palsy (PSP) is a neurodegenerative disease that was first described approximately 50 years ago in 1964. When first described, PSP was thought to have a unique clinical presentation characterised by loss of balance leading to early falls, slowness of movements, stiffness of muscles and loss of the ability to voluntarily move the eyes up and down. Subsequently, it has been recognised that patients who have died and have shown microscopic changes in the brain consistent with PSP had other clinical presentations not involving balance, falls or eye movement problems. The term PSP is, therefore, now best reserved for pathological diagnosis. There have been numerous advances in our understanding of PSP, including the fact that patients with PSP can have many different clinical presentations. In this review, we will focus on the pathological, clinical, neuroimaging and genetic characteristics of PSP.
Key Concepts
Progressive supranuclear palsy (PSP) is a pathological diagnosis.
The cause of PSP is unknown but is thought to be related to abnormal hyperphosphorylated 4R tau.
PSP can present as one of many different clinical syndromes.
Impaired balance with early falls and vertical eye movement problems are highly predictive of PSP pathology.
Atrophy of the premotor cortex, midbrain and superior cerebellar peduncle are the main MRI findings in PSP.
There is some evidence that PSP could have genetic underpinnings.